ATE381335T1 - 2-cyanopyrrolopyrimidine und deren pharmazeutische verwendung - Google Patents

2-cyanopyrrolopyrimidine und deren pharmazeutische verwendung

Info

Publication number
ATE381335T1
ATE381335T1 AT04708332T AT04708332T ATE381335T1 AT E381335 T1 ATE381335 T1 AT E381335T1 AT 04708332 T AT04708332 T AT 04708332T AT 04708332 T AT04708332 T AT 04708332T AT E381335 T1 ATE381335 T1 AT E381335T1
Authority
AT
Austria
Prior art keywords
cyanopyrrolopyrimidines
pharmaceutical use
pharmaceutical
Prior art date
Application number
AT04708332T
Other languages
English (en)
Inventor
Francis Buxton
Takeru Ehara
Pamposh Ganju
Allan Hallett
Ozamu Irie
Atsuko Iwasaki
Takanori Kanazawa
Keiichi Masuya
Kazuhiko Nonomura
Junichi Sakaki
Christopher Snell
Chuanheng Song
Keiko Tanabe
Naoki Teno
Ichiro Umemura
Fumiaki Yokokawa
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0302748A external-priority patent/GB0302748D0/en
Priority claimed from GB0304641A external-priority patent/GB0304641D0/en
Priority claimed from GB0304642A external-priority patent/GB0304642D0/en
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE381335T1 publication Critical patent/ATE381335T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04708332T 2003-02-06 2004-02-05 2-cyanopyrrolopyrimidine und deren pharmazeutische verwendung ATE381335T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0302748A GB0302748D0 (en) 2003-02-06 2003-02-06 Organic compounds
GB0304641A GB0304641D0 (en) 2003-02-28 2003-02-28 Organic compounds
GB0304642A GB0304642D0 (en) 2003-02-28 2003-02-28 Organic compounds

Publications (1)

Publication Number Publication Date
ATE381335T1 true ATE381335T1 (de) 2008-01-15

Family

ID=32854008

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04708332T ATE381335T1 (de) 2003-02-06 2004-02-05 2-cyanopyrrolopyrimidine und deren pharmazeutische verwendung

Country Status (16)

Country Link
US (1) US20060247251A1 (de)
EP (1) EP1592426B1 (de)
JP (1) JP4499667B2 (de)
AR (1) AR043692A1 (de)
AT (1) ATE381335T1 (de)
AU (1) AU2004210422B2 (de)
BR (1) BRPI0407327A (de)
CA (1) CA2514287A1 (de)
DE (1) DE602004010785T2 (de)
ES (1) ES2297378T3 (de)
MX (1) MXPA05008348A (de)
PE (1) PE20050068A1 (de)
PL (1) PL378135A1 (de)
PT (1) PT1592426E (de)
TW (1) TW200420566A (de)
WO (1) WO2004069256A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
GB0304640D0 (en) * 2003-02-28 2003-04-02 Novartis Ag Organic compounds
EP1797883A3 (de) * 2003-04-28 2007-08-01 Novartis AG Pharmezeutische Zusammensetzung einen Cathepsin S Inhibitor und ein Opioid enthaltend
CA2564953A1 (en) * 2004-05-03 2005-11-24 Janssen Pharmaceutica N.V. Novel indole derivatives as selective androgen receptor modulators (sarms)
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
KR101763656B1 (ko) 2009-06-29 2017-08-01 인사이트 홀딩스 코포레이션 Ｐｉ3ｋ 저해물질로서의 피리미디논
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
UY33304A (es) * 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
EP2558463A1 (de) 2010-04-14 2013-02-20 Incyte Corporation Kondensierte derivate als i3-hemmer
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
SG187201A1 (en) 2010-07-26 2013-02-28 Qu Biolog Inc Immunogenic anti-inflammatory compositions
TWI527814B (zh) 2010-12-16 2016-04-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之氮雜苯并咪唑類
TWI515187B (zh) 2010-12-16 2016-01-01 健生科學愛爾蘭無限公司 作為呼吸道融合病毒抗病毒劑之吲哚類
TWI501967B (zh) * 2010-12-16 2015-10-01 Janssen R&D Ireland 作為呼吸道融合病毒抗病毒劑之氮雜吲哚類
EP3660016A1 (de) 2010-12-20 2020-06-03 Incyte Holdings Corporation N-(1-(substituierte phenyl)ethyl)-9h-purin-6-amine als pi3k-hemmer
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
PT3513793T (pt) 2011-09-02 2021-05-10 Incyte Holdings Corp Heterociclilaminas como inibidores de pi3k
CN103304525B (zh) * 2012-03-08 2015-08-05 深圳海王药业有限公司 一种制备达非那新中间体5-(卤代乙基)-2,3-二氢苯并呋喃的方法
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EP2840083B1 (de) * 2012-04-17 2017-09-13 Astellas Pharma Inc. Nitrogenierte bicyclische aromatische heterocyclische verbindung
US20150111868A1 (en) * 2012-06-15 2015-04-23 Jansen R&D Ireland Novel 1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents
MY172021A (en) 2012-10-16 2019-11-12 Janssen Sciences Ireland Uc Rsv antiviral compounds
US9475806B2 (en) 2013-03-14 2016-10-25 Novartis Ag Complement factor B inhibitors and uses there of
CN105849090A (zh) 2013-10-30 2016-08-10 诺华股份有限公司 2-苄基-苯并咪唑补体因子b抑制剂及其用途
TWI671299B (zh) 2014-04-14 2019-09-11 愛爾蘭商健生科學愛爾蘭無限公司 作為ｒｓｖ抗病毒化合物之螺脲化合物
US10251946B2 (en) 2014-05-02 2019-04-09 Qu Biologics Inc. Anti-microbial immunomodulation
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
SG10201907576SA (en) 2015-02-27 2019-09-27 Incyte Corp Salts of pi3k inhibitor and processes for their preparation
US10537552B2 (en) 2015-05-05 2020-01-21 Carafe Drug Innovation, Llc Substituted 5-hydroxyoxindoles and their use as analgesics and fever reducers
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
JP2021500416A (ja) * 2017-10-27 2021-01-07 エステベ ファーマスーティカルズ，ソシエダッド アノニマ 疼痛及び疼痛関連状態を治療するための新規アルコキシアミノ誘導体
SG11202011680YA (en) 2018-06-01 2020-12-30 Incyte Corp Dosing regimen for the treatment of pi3k related disorders
WO2020048829A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 3,9-diazaspiro[5.5]undecane compounds
EP4165034A1 (de) 2020-06-11 2023-04-19 Janssen Sciences Ireland Unlimited Company Hemi (l)-tartrate formen von 3-({5-chlor-1-[3-(methylsulfonyl)propyl)-1h-indol-2 yl} methyl)-1-(2-2,2-trifluorethyl)-1,3-dihydro-2h-imidazo[4,5-c!pyridin-2-on und pharmazeutische zusammensetzungen damit
CN116396202A (zh) * 2023-04-17 2023-07-07 南京优氟医药科技有限公司 一种（2s，4s）-4-氟代吡咯烷-2-羧酸的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034895A1 (de) * 1996-03-15 1997-09-25 Novartis Ag NEUE N-7 HETEROCYCLYL-PYRROLO[2,3-d]PYRIMIDINE UND IHRE VERWENDUNG
US6384041B1 (en) * 1998-06-30 2002-05-07 Eli Lilly And Company Bicyclic sPLA2 inhibitors
GB0100622D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds V111
GB0121033D0 (en) * 2001-08-30 2001-10-24 Novartis Ag Organic compounds
US20030144234A1 (en) * 2001-08-30 2003-07-31 Buxton Francis Paul Methods for the treatment of chronic pain and compositions therefor

Also Published As

Publication number Publication date
CA2514287A1 (en) 2004-08-19
AU2004210422B2 (en) 2008-01-17
MXPA05008348A (es) 2005-11-04
AU2004210422A1 (en) 2004-08-19
WO2004069256A1 (en) 2004-08-19
JP4499667B2 (ja) 2010-07-07
DE602004010785D1 (de) 2008-01-31
PL378135A1 (pl) 2006-03-06
JP2006516554A (ja) 2006-07-06
WO2004069256A8 (en) 2004-10-14
HK1084883A1 (en) 2006-08-11
ES2297378T3 (es) 2008-05-01
BRPI0407327A (pt) 2006-01-10
PE20050068A1 (es) 2005-03-11
US20060247251A1 (en) 2006-11-02
DE602004010785T2 (de) 2008-12-04
EP1592426A1 (de) 2005-11-09
EP1592426B1 (de) 2007-12-19
PT1592426E (pt) 2008-03-13
AR043692A1 (es) 2005-08-10
TW200420566A (en) 2004-10-16

Similar Documents

Publication Publication Date Title
ATE381335T1 (de) 2-cyanopyrrolopyrimidine und deren pharmazeutische verwendung
DE60315892D1 (de) Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung
DE602004021904D1 (de) Gyraseinhibitoren und deren verwendungen
DE60226704D1 (de) Acylierte 6,7,8,9-tetrahydro-5h-benzocycloheptenyl-amine und deren pharmazeutische verwendung
ATE517081T1 (de) Hydroxamsäureester und deren pharmazeutische verwendung
DE60138768D1 (de) Glucopyranosylpyrazolderivate und deren verwendung in arzneimitteln
ATA13842001A (de) Chitosan-thio-alkyl-amidin konjugate und deren kosmetische sowie pharmazeutische verwendung
ATE459647T1 (de) Humane il-18 substitutionsmutanten und deren konjugate
DE602004020474D1 (de) Vegf-traps und deren therapeutische anwendungen
DE60208351D1 (de) Glukopyranosyloxybenzylbenzolderivate und deren medizinische verwendung
DE60237580D1 (de) Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
ATE524178T1 (de) Acylierte, heteroaryl-kondensierte cycloalkenylamine und deren verwendung als arzneimittel
ATE529420T1 (de) 3-ä(2-ää4-hexyloxycarbonylamino-imino-methyl)- phenylaminoü-methylü-1-methyl-1h-benzimidazol-5 carbonyl)-pyridin-2-yl-aminoü-propionsäure- ethylester-methansulfonat-hemihydrat und dessen verwendung als arzneimittel
ATE381333T1 (de) Glucocorticoid-mimetika, deren herstellung, pharmazeutische zusammensetzungen und verwendung
ATE420084T1 (de) Neue imidazolderivate und deren verwendung als pharmazeutische mittel
DE602004027354D1 (de) SUBSTITUIERTE 8y-PYRIDINYLDIHYDROSPIROiCYCLOALKYL PYRIMIDOi1,2-A PYRIMIDIN-6-ON- UND 8y-PYRIMIDINYLDIHYDROSPIROiCYCLOALKYL PYRIMIDOi1,2-A PYRIMIDIN-6-ONDERIVATE UND DEREN VERWENDUNG BEI NEURODEGENERATIVEN KRANKHEITEN
DE60224194D1 (de) Arzneizusammensetzungen enthaltend terbinafin und deren verwendung
DE502004000891D1 (de) Organosilylfunktionalisierte partikel und deren herstellung
DE50206476D1 (de) Cyanoanthranylamid-derivate und deren verwendung als arzneimittel
DE602004030564D1 (de) 2-substituierte phenyl-5,7-dialkyl-3,7-dihydropyrrolä2,3-dü pyrimidin-4-onderivate, deren herstellung und pharmazeutische verwendung
DE602004022169D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
DE60336999D1 (de) Melatonin enthaltende pharmazeutische formulierung
DE60310526D1 (de) Ivabradin enthaltende pharmazeutische zusammensetzung mit oraler dispersion
EP1750693A4 (de) Okuloselektive arzneimittel und prodrugs
ATE555097T1 (de) 4-cycloalkyl-substituierte tetrahydrochinolinderivate und deren verwendung als medikamente

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1592426

Country of ref document: EP

REN Ceased due to non-payment of the annual fee